{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T07:20:02Z","timestamp":1773732002442,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001061","name":"Rebecca L. Cooper Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001061","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swinburne University of Technology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s40263-023-01046-z","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T17:02:31Z","timestamp":1699549351000},"page":"981-992","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A Semi-Naturalistic, Open-Label Trial Examining the Effect of Prescribed Medical Cannabis on Neurocognitive Performance"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8559-6995","authenticated-orcid":false,"given":"Thomas R.","family":"Arkell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5233-8191","authenticated-orcid":false,"given":"Brooke","family":"Manning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5670-3192","authenticated-orcid":false,"given":"Luke A.","family":"Downey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4470-4718","authenticated-orcid":false,"given":"Amie C.","family":"Hayley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"key":"1046_CR1","unstructured":"Therapeutic Goods Administration. Medicinal Cannabis Special Access Scheme Category B data. Medicinal Cannabis 2023. https:\/\/www.tga.gov.au\/medicinal-cannabis-special-access-scheme-category-b-data. Accessed 24 May 2023"},{"key":"1046_CR2","unstructured":"Therapeutic Goods Administration. Medicinal cannabis: Access pathways and patient access data. Medicinal cannabis hub 2023. https:\/\/www.tga.gov.au\/products\/unapproved-therapeutic-goods\/medicinal-cannabis-hub\/medicinal-cannabis-access-pathways-and-patient-access-data. Accessed 24 May 2023"},{"issue":"7","key":"1046_CR3","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.biopsych.2015.12.002","volume":"79","author":"SJ Broyd","year":"2016","unstructured":"Broyd SJ, van Hell HH, Beale C, Yucel M, Solowij N. Acute and chronic effects of cannabinoids on human cognition-a systematic review. Biol Psychiatry. 2016;79(7):557\u201367. https:\/\/doi.org\/10.1016\/j.biopsych.2015.12.002.","journal-title":"Biol Psychiatry"},{"issue":"3","key":"1046_CR4","first-page":"180","volume":"42","author":"MB Bridgeman","year":"2017","unstructured":"Bridgeman MB, Abazia DT. Medicinal cannabis: history, pharmacology, and implications for the acute care setting. P T. 2017;42(3):180\u20138.","journal-title":"P T"},{"issue":"3","key":"1046_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.pneurobio.2011.01.002","volume":"93","author":"O Moriarty","year":"2011","unstructured":"Moriarty O, McGuire BE, Finn DP. The effect of pain on cognitive function: a review of clinical and preclinical research. Prog Neurobiol. 2011;93(3):385\u2013404. https:\/\/doi.org\/10.1016\/j.pneurobio.2011.01.002.","journal-title":"Prog Neurobiol"},{"issue":"5","key":"1046_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.12522","volume":"6","author":"TR Arkell","year":"2023","unstructured":"Arkell TR, Downey LA, Hayley AC, Roth S. Assessment of medical cannabis and health-related quality of life. JAMA Netw Open. 2023;6(5): e2312522. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.12522.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"1046_CR7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12954-022-00666-w","volume":"19","author":"N Lintzeris","year":"2022","unstructured":"Lintzeris N, Mills L, Abelev SV, Suraev A, Arnold JC, McGregor IS. Medical cannabis use in Australia: consumer experiences from the online cannabis as medicine survey 2020 (CAMS-20). Harm Reduct J. 2022;19(1):88. https:\/\/doi.org\/10.1186\/s12954-022-00666-w.","journal-title":"Harm Reduct J"},{"issue":"4","key":"1046_CR8","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.cger.2013.07.002","volume":"29","author":"CN Harada","year":"2013","unstructured":"Harada CN, Natelson Love MC, Triebel KL. Normal cognitive aging. Clin Geriatr Med. 2013;29(4):737\u201352. https:\/\/doi.org\/10.1016\/j.cger.2013.07.002.","journal-title":"Clin Geriatr Med"},{"issue":"1","key":"1046_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00406-019-00981-7","volume":"269","author":"C Gorey","year":"2019","unstructured":"Gorey C, Kuhns L, Smaragdi E, Kroon E, Cousijn J. Age-related differences in the impact of cannabis use on the brain and cognition: a systematic review. Eur Arch Psychiatry Clin Neurosci. 2019;269(1):37\u201358. https:\/\/doi.org\/10.1007\/s00406-019-00981-7.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"1","key":"1046_CR10","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-022-02073-5","volume":"11","author":"A Wieghorst","year":"2022","unstructured":"Wieghorst A, Roessler KK, Hendricks O, Andersen TE. The effect of medical cannabis on cognitive functions: a systematic review. Syst Rev. 2022;11(1):210. https:\/\/doi.org\/10.1186\/s13643-022-02073-5.","journal-title":"Syst Rev"},{"issue":"3","key":"1046_CR11","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00228-023-03454-y","volume":"79","author":"E Motaghi","year":"2023","unstructured":"Motaghi E, Ghasemi-Pirbaluti M, Rashidi M, Alasvand M, Di Ciano P, Bozorgi H. The effect of tetrahydrocannabinol:cannabidiol oromucosal spray on cognition: a systematic review. Eur J Clin Pharmacol. 2023;79(3):371\u201381. https:\/\/doi.org\/10.1007\/s00228-023-03454-y.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"1046_CR12","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1017\/S1355617721000114","volume":"27","author":"KA Sagar","year":"2021","unstructured":"Sagar KA, Dahlgren MK, Lambros AM, Smith RT, El-Abboud C, Gruber SA. An observational, longitudinal study of cognition in medical cannabis patients over the course of 12 months of treatment: preliminary results. J Int Neuropsychol Soc. 2021;27(6):648\u201360. https:\/\/doi.org\/10.1017\/S1355617721000114.","journal-title":"J Int Neuropsychol Soc"},{"issue":"2","key":"1046_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/jat\/bkx012","volume":"41","author":"R Vandrey","year":"2017","unstructured":"Vandrey R, Herrmann ES, Mitchell JM, Bigelow GE, Flegel R, LoDico C, et al. Pharmacokinetic profile of oral cannabis in humans: blood and oral fluid disposition and relation to pharmacodynamic outcomes. J Anal Toxicol. 2017;41(2):83\u201399. https:\/\/doi.org\/10.1093\/jat\/bkx012.","journal-title":"J Anal Toxicol"},{"issue":"7","key":"1046_CR14","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/1099-1077(200010)15:7<551::AID-HUP236>3.0.CO;2-P","volume":"15","author":"JG Ramaekers","year":"2000","unstructured":"Ramaekers JG, Robbe HW, O\u2019Hanlon JF. Marijuana, alcohol and actual driving performance. Hum Psychopharmacol. 2000;15(7):551\u20138. https:\/\/doi.org\/10.1002\/1099-1077(200010)15:7%3c551::AID-HUP236%3e3.0.CO;2-P.","journal-title":"Hum Psychopharmacol"},{"issue":"7","key":"1046_CR15","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1177\/02698811211021583","volume":"35","author":"TR Spindle","year":"2021","unstructured":"Spindle TR, Martin EL, Grabenauer M, Woodward T, Milburn MA, Vandrey R. Assessment of cognitive and psychomotor impairment, subjective effects, and blood THC concentrations following acute administration of oral and vaporized cannabis. J Psychopharmacol. 2021;35(7):786\u2013803. https:\/\/doi.org\/10.1177\/02698811211021583.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"1046_CR16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1089\/can.2020.0048","volume":"7","author":"HC Karoly","year":"2022","unstructured":"Karoly HC, Milburn MA, Brooks-Russell A, Brown M, Streufert J, Bryan AD, et al. Effects of high-potency cannabis on psychomotor performance in frequent cannabis users. Cannabis Cannabinoid Res. 2022;7(1):107\u201315. https:\/\/doi.org\/10.1089\/can.2020.0048.","journal-title":"Cannabis Cannabinoid Res."},{"issue":"21","key":"1046_CR17","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1001\/jama.2020.21218","volume":"324","author":"TR Arkell","year":"2020","unstructured":"Arkell TR, Vinckenbosch F, Kevin RC, Theunissen EL, McGregor IS, Ramaekers JG. Effect of cannabidiol and delta9-tetrahydrocannabinol on driving performance: a randomized clinical trial. JAMA. 2020;324(21):2177\u201386. https:\/\/doi.org\/10.1001\/jama.2020.21218.","journal-title":"JAMA"},{"issue":"12","key":"1046_CR18","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1177\/02698811221095356","volume":"36","author":"D McCartney","year":"2022","unstructured":"McCartney D, Suraev AS, Doohan PT, Irwin C, Kevin RC, Grunstein RR, et al. Effects of cannabidiol on simulated driving and cognitive performance: a dose-ranging randomised controlled trial. J Psychopharmacol. 2022;36(12):1338\u201349. https:\/\/doi.org\/10.1177\/02698811221095356.","journal-title":"J Psychopharmacol"},{"issue":"10","key":"1046_CR19","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1503\/cmaj.110837","volume":"184","author":"J Corey-Bloom","year":"2012","unstructured":"Corey-Bloom J, Wolfson T, Gamst A, Jin S, Marcotte TD, Bentley H, et al. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. CMAJ. 2012;184(10):1143\u201350. https:\/\/doi.org\/10.1503\/cmaj.110837.","journal-title":"CMAJ"},{"issue":"7","key":"1046_CR20","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jpain.2015.03.008","volume":"16","author":"MS Wallace","year":"2015","unstructured":"Wallace MS, Marcotte TD, Umlauf A, Gouaux B, Atkinson JH. Efficacy of inhaled cannabis on painful diabetic neuropathy. J Pain. 2015;16(7):616\u201327. https:\/\/doi.org\/10.1016\/j.jpain.2015.03.008.","journal-title":"J Pain"},{"issue":"6","key":"1046_CR21","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jpain.2007.12.010","volume":"9","author":"B Wilsey","year":"2008","unstructured":"Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain. 2008;9(6):506\u201321. https:\/\/doi.org\/10.1016\/j.jpain.2007.12.010.","journal-title":"J Pain"},{"issue":"2","key":"1046_CR22","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jpain.2012.10.009","volume":"14","author":"B Wilsey","year":"2013","unstructured":"Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain. 2013;14(2):136\u201348. https:\/\/doi.org\/10.1016\/j.jpain.2012.10.009.","journal-title":"J Pain"},{"issue":"3","key":"1046_CR23","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jamapsychiatry.2021.4037","volume":"79","author":"TD Marcotte","year":"2022","unstructured":"Marcotte TD, Umlauf A, Grelotti DJ, Sones EG, Sobolesky PM, Smith BE, et al. Driving performance and cannabis users\u2019 perception of safety: a randomized clinical trial. JAMA Psychiat. 2022;79(3):201\u20139. https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.4037.","journal-title":"JAMA Psychiat"},{"issue":"6","key":"1046_CR24","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1212\/01.wnl.0000176753.45410.8b","volume":"65","author":"DJ Rog","year":"2005","unstructured":"Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65(6):812\u20139. https:\/\/doi.org\/10.1212\/01.wnl.0000176753.45410.8b.","journal-title":"Neurology"},{"issue":"1","key":"1046_CR25","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/npp.2017.209","volume":"43","author":"DL Boggs","year":"2018","unstructured":"Boggs DL, Nguyen JD, Morgenson D, Taffe MA, Ranganathan M. Clinical and preclinical evidence for functional interactions of cannabidiol and delta(9)-tetrahydrocannabinol. Neuropsychopharmacology. 2018;43(1):142\u201354. https:\/\/doi.org\/10.1038\/npp.2017.209.","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"1046_CR26","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.mehy.2005.08.026","volume":"66","author":"E Russo","year":"2006","unstructured":"Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses. 2006;66(2):234\u201346. https:\/\/doi.org\/10.1016\/j.mehy.2005.08.026.","journal-title":"Med Hypotheses"},{"issue":"9","key":"1046_CR27","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1007\/s00213-019-05246-8","volume":"236","author":"TR Arkell","year":"2019","unstructured":"Arkell TR, Lintzeris N, Kevin RC, Ramaekers JG, Vandrey R, Irwin C, et al. Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Psychopharmacology. 2019;236(9):2713\u201324. https:\/\/doi.org\/10.1007\/s00213-019-05246-8.","journal-title":"Psychopharmacology"},{"issue":"8","key":"1046_CR28","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1038\/npp.2015.367","volume":"41","author":"M Haney","year":"2016","unstructured":"Haney M, Malcolm RJ, Babalonis S, Nuzzo PA, Cooper ZD, Bedi G, et al. Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis. Neuropsychopharmacology. 2016;41(8):1974\u201382. https:\/\/doi.org\/10.1038\/npp.2015.367.","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"1046_CR29","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.54752","volume":"6","author":"CA Zamarripa","year":"2023","unstructured":"Zamarripa CA, Spindle TR, Surujunarain R, Weerts EM, Bansal S, Unadkat JD, et al. Assessment of orally administered Delta9-tetrahydrocannabinol when coadministered with cannabidiol on Delta9-tetrahydrocannabinol pharmacokinetics and pharmacodynamics in healthy adults: a randomized clinical trial. JAMA Netw Open. 2023;6(2): e2254752. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.54752.","journal-title":"JAMA Netw Open"},{"issue":"9","key":"1046_CR30","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/s41583-021-00500-5","volume":"22","author":"TR Arkell","year":"2021","unstructured":"Arkell TR, Hayley AC, Downey LA. Managing the high: developing legislation and detection methods for cannabis impairment. Nat Rev Neurosci. 2021;22(9):584. https:\/\/doi.org\/10.1038\/s41583-021-00500-5.","journal-title":"Nat Rev Neurosci"},{"issue":"8","key":"1046_CR31","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1002\/cbdv.200790152","volume":"4","author":"MA Huestis","year":"2007","unstructured":"Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4(8):1770\u2013804. https:\/\/doi.org\/10.1002\/cbdv.200790152.","journal-title":"Chem Biodivers"},{"key":"1046_CR32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.neubiorev.2021.01.003","volume":"126","author":"D McCartney","year":"2021","unstructured":"McCartney D, Arkell TR, Irwin C, McGregor IS. Determining the magnitude and duration of acute Delta(9)-tetrahydrocannabinol (Delta(9)-THC)-induced driving and cognitive impairment: A systematic and meta-analytic review. Neurosci Biobehav Rev. 2021;126:175\u201393. https:\/\/doi.org\/10.1016\/j.neubiorev.2021.01.003.","journal-title":"Neurosci Biobehav Rev"},{"issue":"10","key":"1046_CR33","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1111\/j.1360-0443.2012.03928.x","volume":"107","author":"WM Bosker","year":"2012","unstructured":"Bosker WM, Kuypers KP, Theunissen EL, Surinx A, Blankespoor RJ, Skopp G, et al. Medicinal \u03949-tetrahydrocannabinol (dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is not detected in Standard Field Sobriety Tests. Addiction. 2012;107(10):1837\u201344. https:\/\/doi.org\/10.1111\/j.1360-0443.2012.03928.x.","journal-title":"Addiction"},{"issue":"3","key":"1046_CR34","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1177\/0269881108092393","volume":"23","author":"JG Ramaekers","year":"2009","unstructured":"Ramaekers JG, Kauert G, Theunissen EL, Toennes SW, Moeller MR. Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J Psychopharmacol. 2009;23(3):266\u201377. https:\/\/doi.org\/10.1177\/0269881108092393.","journal-title":"J Psychopharmacol"},{"issue":"2","key":"1046_CR35","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00213-010-2042-1","volume":"214","author":"JG Ramaekers","year":"2011","unstructured":"Ramaekers JG, Theunissen EL, de Brouwer M, Toennes SW, Moeller MR, Kauert G. Tolerance and cross-tolerance to neurocognitive effects of THC and alcohol in heavy cannabis users. Psychopharmacology. 2011;214(2):391\u2013401. https:\/\/doi.org\/10.1007\/s00213-010-2042-1.","journal-title":"Psychopharmacology"},{"key":"1046_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neubiorev.2018.07.014","volume":"93","author":"M Colizzi","year":"2018","unstructured":"Colizzi M, Bhattacharyya S. Cannabis use and the development of tolerance: a systematic review of human evidence. Neurosci Biobehav Rev. 2018;93:1\u201325. https:\/\/doi.org\/10.1016\/j.neubiorev.2018.07.014.","journal-title":"Neurosci Biobehav Rev"},{"key":"1046_CR37","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.euroneuro.2020.01.006","volume":"36","author":"JG Ramaekers","year":"2020","unstructured":"Ramaekers JG, Mason NL, Theunissen EL. Blunted highs: Pharmacodynamic and behavioral models of cannabis tolerance. Eur Neuropsychopharmacol. 2020;36:191\u2013205. https:\/\/doi.org\/10.1016\/j.euroneuro.2020.01.006.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"1046_CR38","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12870","volume":"26","author":"NL Mason","year":"2021","unstructured":"Mason NL, Theunissen EL, Hutten N, Tse DHY, Toennes SW, Jansen JFA, et al. Reduced responsiveness of the reward system is associated with tolerance to cannabis impairment in chronic users. Addict Biol. 2021;26(1): e12870. https:\/\/doi.org\/10.1111\/adb.12870.","journal-title":"Addict Biol"},{"key":"1046_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104684","volume":"137","author":"D McCartney","year":"2022","unstructured":"McCartney D, Arkell TR, Irwin C, McGregor IS. Response to: cannabis use before safety sensitive work: what delay is prudent? Neurosci Biobehav Rev. 2022;137: 104684. https:\/\/doi.org\/10.1016\/j.neubiorev.2022.104684.","journal-title":"Neurosci Biobehav Rev"},{"issue":"6","key":"1046_CR40","doi-asserted-by":"publisher","first-page":"357","DOI":"10.31128\/AJGP-02-21-5840","volume":"50","author":"TR Arkell","year":"2021","unstructured":"Arkell TR, McCartney D, McGregor IS. Medical cannabis and driving. Aust J Gen Pract. 2021;50(6):357\u201362. https:\/\/doi.org\/10.31128\/AJGP-02-21-5840.","journal-title":"Aust J Gen Pract."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01046-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-023-01046-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01046-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T12:21:21Z","timestamp":1700742081000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-023-01046-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1046"],"URL":"https:\/\/doi.org\/10.1007\/s40263-023-01046-z","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"18 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by CAUL and its Member Institutions. This research was partially funded by grants to ACH and LAD from the Rebecca Cooper Foundation and Australia\u2019s National Health and Medical Research Council, as well as a Research Training Program Stipend from Swinburne University to BM.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Thomas R. Arkell reports receiving speaker fees from Althea, NUBU Pharmaceuticals, and the International College of Cannabinoid Medicine, as well as grants from the Barbara Dicker Foundation outside the submitted work. Brooke Manning reports no conflicts of interest. Luke A. Downey reports receiving grants from the National Health and Medical Research Council, grants from Cannvalate, and grants from the Barbara Dicker Foundation outside the submitted work. Amie C. Haley reports receiving grants from Cannvalate, the Rebecca L. Cooper Foundation for the Al and Val Rosenstrauss Fellowship (F2021894), the Barbara Dicker Foundation, and the Road Safety Innovation Fund outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Requests for access to study data can be submitted to the corresponding author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data And Material"}},{"value":"All procedures were approved by the Swinburne University Human Research Ethics Committee and conducted in accordance with the Declaration of Helsinki.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All participants provided written, informed consent prior to participating.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualization: TRA, LAD, ACH. Data acquisition: TRA, ACH. Statistical analysis: TRA, BM. Drafting of the manuscript: TRA. Reviewing and editing: BM, LAD, ACH. All authors reviewed the manuscript, revised it critically for important intellectual content, have read and approved the final submitted manuscript, and agree to be accountable for this work.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}